Cardiorenal metabolic disease

1 paper1 finding

Interventions

1

SGLT2 inhibitors

downin humans1

1 study

SGLT2 inhibitors protect against cardiorenal metabolic disease in humans.
“protect the kidneys and heart of patients with or without type 2 diabetes mellitus”
Reviewin patients with or without type 2 diabetes mellitus
Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming
EBioMedicineAug 13, 2022

More on SGLT2 inhibitors

Latest

2 in 12 months

Frontiers in EndocrinologyOct 8

Insulin resistance, metabolic phenotypes, and the obesity paradox: a triglyceride glucose-body mass index framework in partial kidney diseases

ReviewKidney disease

AHA Scientific Sessions 2025 AbstractNov 3

Physical activity, cardiorenal metabolic diseases and multimorbidity: a prospective study of UK Biobank

Cohort study of 328,147 peoplePopulations

CellsFeb 26

The Role of CD38 in the Pathogenesis of Cardiorenal Metabolic Disease and Aging, an Approach from Basic Research

ReviewNAD+ metabolism

EBioMedicineAug 13

Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming

ReviewSGLT2 inhibitors